A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

NCT02988960 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

163

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors Cancer

Interventions

DRUG: ABBV-927
DRUG: ABBV-927
DRUG: ABBV-181

Sponsor

AbbVie